We are live on ! Find out more
VIA

Vident Investment Advisory Portfolio holdings

AUM $2.9B
1-Year Est. Return 24.67%
This Fund
S&P 500
This Quarter Est. Return
+3.07%
1 Year Est. Return
+24.67%
3 Year Est. Return
+82.63%
5 Year Est. Return
+113.33%
10 Year Est. Return
–
AUM
$1.62M
AUM Growth
-$789M
Cap. Flow
+$604M
Cap. Flow %
37,256.4%
Top 10 Hldgs %
16.56%
Holding
402
New
38
Increased
331
Reduced
2
Closed
31

Top Buys

Rank Stock Value
1
AMZN icon
Amazon
AMZN
+$12M
2
MSFT icon
Microsoft
MSFT
+$9.07M
3
AGN
Allergan plc
AGN
+$7.27M
4
GOOG icon
Alphabet (Google) Class C
GOOG
+$6.34M
5
BRK.B icon
Berkshire Hathaway Class B
BRK.B
+$6.22M

Top Sells

Rank Stock Value
1
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$91.8M
2
HNT
HEALTH NET INC
HNT
+$2.13M
3
EFA icon
iShares MSCI EAFE ETF
EFA
+$1.93M
4
CLVS
Clovis Oncology, Inc.
CLVS
+$1.48M
5
DUK icon
Duke Energy
DUK
+$1.47M

Sector Composition

Rank Sector Weight
1 Industrials 20.52%
2 Technology 12.84%
3 Financials 11.72%
4 Healthcare 11.37%
5 Consumer Discretionary 11.33%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CYAD
351
DELISTED
Celyad Oncology SA American Depositary Shares
CYAD
$966 0.06%
21,872
+6,690
+44% +$273K
IMDZ
352
DELISTED
Immune Design Corp.
IMDZ
$956 0.06%
73,608
+35,224
+92% +$407K
CTMX icon
353
CytomX Therapeutics
CTMX
$754M
$952 0.06%
73,830
+35,328
+92% +$491K
KITE
354
DELISTED
Kite Pharma, Inc.
KITE
$940 0.06%
20,466
+9,494
+87% +$460K
MKSI icon
355
MKS Inc
MKSI
$20.6B
$902 0.06%
23,980
+11,652
+95% +$398K
IOVA icon
356
Iovance Biotherapeutics
IOVA
$2.87B
$898 0.06%
176,720
+84,567
+92% +$463K
MGNX icon
357
MacroGenics
MGNX
$257M
$858 0.05%
45,742
+21,890
+92% +$417K
ATRA icon
358
Atara Biotherapeutics
ATRA
$76.1M
$802 0.05%
1,687
+787
+87% +$354K
BIDU icon
359
Baidu
BIDU
$37.2B
$750 0.05%
3,926
+2,608
+198% +$444K
IBRX icon
360
ImmunityBio
IBRX
$8.1B
$744 0.05%
90,444
+42,208
+88% +$398K
LUMO
361
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$718 0.04%
4,388
+2,048
+88% +$415K
BLCM
362
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$708 0.04%
7,574
+3,534
+87% +$385K
TEVA icon
363
Teva Pharmaceuticals
TEVA
$41.2B
$682 0.04%
12,734
+9,121
+252% +$535K
WM icon
364
Waste Management
WM
$91B
$642 0.04%
10,886
+2,606
+31% +$144K
UGI icon
365
UGI
UGI
$7.33B
$638 0.04%
15,812
+7,684
+95% +$279K
KDNY
366
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$602 0.04%
9,392
+4,383
+88% +$355K
CLDX icon
367
Celldex Therapeutics
CLDX
$3.28B
$350 0.02%
6,180
+2,884
+88% +$324K
MRO
368
DELISTED
Marathon Oil Corporation
MRO
$248 0.02%
22,220
+11,788
+113% +$110K
FCX icon
369
Freeport-McMoran
FCX
$97.5B
$226 0.01%
21,908
+3,989
+22% +$28K
S
370
DELISTED
Sprint Corporation
S
$202 0.01%
57,834
+29,688
+105% +$94.9K
VER
371
DELISTED
VEREIT, Inc.
VER
$190 0.01%
4,287
+1,096
+34% +$43.5K
BBWI icon
372
Bath & Body Works
BBWI
$4.1B
– –
-17,765
Closed -$1.38M
BIIB icon
373
Biogen
BIIB
$30.7B
– –
-4,708
Closed -$1.44M
BKNG icon
374
Booking.com
BKNG
$161B
– –
-25,650
Closed -$1.31M
BLDR icon
375
Builders FirstSource
BLDR
$8.04B
– –
-98,376
Closed -$1.09M
13 14
15
16 17

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
WI
Winder Investment Singapore $4.4B AUM 8.87% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return

Vident Investment Advisory's Q1 2016 Portfolio in Review

As of Q1 2016, Vident Investment Advisory held 402 positions worth $1.62M, down 100% from $791M the previous quarter. Its ten largest holdings account for 17% of the portfolio.

Vident Investment Advisory deployed $604M of net new capital in Q1 2016, opening 38 new positions and adding to 331 existing holdings. Its largest new stake was Alphabet (Google) Class C: 177,120 shares worth $6.6K.

By sector, the portfolio is most concentrated in Industrials at 21% of assets, up from 9.8% a quarter earlier, followed by Technology and Financials.

On the sell side, the largest reduction was TIME WARNER CABLE INC NEW COM STK, an estimated $684K trimmed.

  • Vident Investment Advisory's largest Q1 2016 buy was Alphabet (Google) Class C: 177,120 shares worth $6.6K.
  • Vident Investment Advisory added most to Amazon in Q1 2016, an estimated $12M increase.
  • Vident Investment Advisory's biggest Q1 2016 reduction was TIME WARNER CABLE INC NEW COM STK, cutting an estimated $684K.
  • Vident Investment Advisory fully exited State Street SPDR S&P 500 ETF Trust in Q1 2016, selling an estimated $91.8M.
  • Vident Investment Advisory's ten largest holdings make up 17% of its $1.62M portfolio in Q1 2016.
  • Vident Investment Advisory opened 38 new positions and closed 31 in Q1 2016.
  • Vident Investment Advisory's portfolio value fell 100% quarter-over-quarter to $1.62M.

Based on Vident Investment Advisory's 13F filing for Q1 2016, filed 23 May 2016.